Characterization of high-resolution detector response for stereotactic patient-specific QA across different TPS-linac systems
Radiation and Environmental Biophysics, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Basım Tarihi: 2026
- Doi Numarası: 10.1007/s00411-026-01256-1
- Dergi Adı: Radiation and Environmental Biophysics
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Compendex, EMBASE, Environment Index, INSPEC, MEDLINE, Natural Science Collection (ProQuest), Biological Science Database (ProQuest), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
- Anahtar Kelimeler: High-resolution detector, myQA SRS, PSQA, SBRT, SRS
- Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet
Özet
This study aimed to characterize the response and inter-system consistency of a high-resolution myQA SRS detector used for patient-specific quality assurance (PSQA) across different configurations of treatment planning system and linear accelerator (TPS–linac). A total of 20 clinically approved stereotactic radiosurgery / stereotactic body radiotherapy (SRS/SBRT) cases were included in a paired-study design to eliminate patient-specific anatomical bias. Each case was re-optimized on both Monaco–Versa HD (Agility 160 MLC) and Eclipse–TrueBeam STx (HD120 MLC) platforms, resulting in 40 unique plans. Doses from all plans were measured using the myQA SRS detector, with TrueBeam-based plans additionally verified via an electronic portal imaging device (EPID) for comparative detector analysis. Gamma passing rates (GPRs) (2%/1 mm to 3%/2 mm) and plan complexity metrics, including monitor units (MUs), segment number, and Modulation Factor (MF), were evaluated using non-parametric statistics. For the myQA SRS, mean GPRs ranged from 85.1% to 95.5% for Monaco and 80.6% to 92.9% for Eclipse, with no statistically significant differences observed between platforms (p > 0.05). Spearman’s analysis confirmed that plan complexity did not correlate with QA outcomes (p > 0.05), indicating that the detector’s response remains independent of modulation levels within clinical ranges. Comparative analysis between myQA SRS and EPID revealed systematic detector-dependent differences that became more pronounced at wider gamma criteria. Isolated low-passing outlier cases, associated with very small targets in steep dose-gradient regions, were observed for both detectors and were analyzed separately. Overall, the myQA SRS detector demonstrated high inter-system consistency, and appears to be a robust tool for PSQA of highly modulated stereotactic plans. The findings suggest that PSQA outcomes are more influenced by system-specific modelling and detector characteristics than by plan complexity alone.